{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Lung Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Sepsis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Hypoalbuminemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hypokalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Blood Bilirubin Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Dehydration"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The frequency and severity of toxicity events will be evaluated. All adverse events will be summarized as to type, severity, frequency, timing and attribution. Grade 3 or greater AEs that occurred in at least 10% of the patients are reported here","groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Evaluated once per cycle (1 cycle=28 days) up to 1 year.","title":"Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}